FDA Issues Early Alert on Baxter Intravascular Administration Sets

FDA Issues Early Alert on Baxter Intravascular Administration Sets

FDA CDRH has issued an Early Alert concerning certain lots of Baxter Duo-Vent intravascular administration sets that may allow air bubbles to enter the tubing and create a risk of air embolism. The affected product includes product code 1C8507 and three lot numbers. FDA and Baxter recommend immediate discontinuation of use, quarantine, and return. Manufacturers should assess the impact on existing registrations, check inventory and distributor management, and update post-market surveillance plans.

Key Summary

FDA CDRH issued an Early Alert regarding certain lots of Baxter Duo-Vent infusion sets that may present a risk of air embolism if air bubbles enter the tubing. The affected product includes product code 1C8507 and three lot numbers. Immediate discontinuation of use, quarantine, and return are recommended. Companies should assess the impact on existing registrations, review inventory and distributor management, and update post-market surveillance plans.

Source and Applicability

Source organization: FDA CDRH News & Updates

Original publication date listed by the source: July 17, 2026

Article headline date: July 9, 2026

Source: FDA CDRH News & Updates

This article is based on publicly available information from FDA CDRH News & Updates at https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-administration-set-issue-baxter. The latest official publication by the regulatory authority prevails.

Full Translation of the Core FDA Content

CDRH is issuing this Early Alert to notify the public about a potential high-risk device issue. FDA will keep the public informed and will update this page as important new information becomes available.

Affected Products

FDA is aware that Baxter has sent letters to affected customers recommending that certain Duo-Vent infusion sets be removed from locations where they are used or sold.

Affected device:

• Product code: 1C8507
• Product description: Duo-Vent infusion set and male luer lock adapter. 10 drops/mL. 109 inches (2.8 m). Sterile packaging.
• Lot numbers: DR26C27062, DR26D14031, DR26E13055
• UDI-DI: 00085412014319

Actions to Take

Do not use the affected product. Immediately identify, quarantine, and return the affected lots.

On June 30, Baxter sent letters to all affected customers recommending the following actions:

• Immediately locate, quarantine, and stop using products with the affected lot numbers. Product codes and lot numbers can be found on the individual product packaging and shipping cartons.
• Contact Baxter Healthcare Services to arrange return and replacement.
• If you purchased this product from a distributor or wholesaler, contact them to arrange return of the affected product.
• Forward a copy of the letter to the director of nursing, director of pharmacy, director of purchasing, facility risk manager, and any other department in your institution that uses the affected product.
• If you are a distributor, wholesaler, distributor/reseller, or original equipment manufacturer (OEM) that has distributed any affected product to other organizations, conduct a user-level recall of the product you distributed to your customers.
• Check this page for updates. FDA is currently reviewing information about this potential high-risk device issue and will continue to inform the public as important new information becomes available.

Reason for the Alert

Baxter states that in certain lots of Duo-Vent infusion sets, air bubbles may appear in the drip chamber and tubing when a pressure cuff is used or when the line is flushed in the fully open position.

When the bag is pressurized, for example by a pressure cuff, or when the line is flushed in the fully open state, air may enter the infusion set. If an infusion pump with an air detector is not used, as may be the case during pressure infusion, there is a potential risk that air may be delivered to the patient through the intravenous line.

In most cases, a small amount of air can be absorbed in the lungs without harm. However, in some patients with cardiac or vascular conditions, such as patent foramen ovale or other right-to-left shunt, air in the circulation may lead to serious adverse events, including stroke, myocardial ischemia, or death.

As of July 15, Baxter reported no serious injuries or deaths related to this issue.

Device Use

The Duo-Vent infusion set is used to infuse fluids from a container into a patient's vascular system through a vascular access device.

Contact Information

US customers who experience adverse reactions, quality problems, or have questions about this issue should contact Baxter at (888) 229-0001.

Unique Device Identification (UDI)

UDI helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. UDI enables more accurate reporting, review, and analysis of adverse event reports, allowing faster identification of devices and potential correction of problems.

How to Report Problems

Healthcare professionals and consumers can report adverse reactions or quality problems experienced with the use of these devices to MedWatch, FDA's safety information and adverse event reporting program.

What This Means for Medical Device Companies

Information such as this from FDA CDRH News & Updates should first be incorporated into a company's regulatory intelligence and post-market surveillance scope, not treated merely as general news. Companies should determine whether the update is a guidance document, recall/safety information, product approval, digital health information, quality system information, or post-market regulatory information, and confirm whether it may affect existing registration projects or products under development.

If the content involves a specific product, test performance, risk warning, or regulatory action, companies should further assess whether it affects product classification, 510(k), De Novo, PMA pathway, technical documentation, labels and instructions for use, quality system records, or post-market reporting obligations. For companies pursuing US market registration, the original link, publication date, scope of application, and internal conclusions should be recorded in the project tracker.

What Materials Should Companies Review?

Companies should check the basis for product classification, applicable regulatory provisions, predicate device or substantial equivalence assessment, performance testing, software and cybersecurity documentation, risk management, clinical evidence, labels and instructions for use, and quality system readiness.

Common Risks

Common risks include misjudging the FDA pathway, overlooking changes in guidance documents, insufficient performance test design, overly broad labeling claims, unclear post-market reporting obligations, and directly applying materials from other markets to US registration.

AIMEILI Regulatory Interpretation

This FDA Early Alert concerns Baxter Duo-Vent infusion sets and the potential for air entering the tubing and causing serious air embolism risk. Although no serious injuries or deaths had been reported as of July 15, the alert reminds medical device companies that potential safety hazards must receive close attention in the post-market phase.

For Chinese medical device companies, the first step is to check whether their own products involve a similar design defect. If a company exports similar infusion sets to the United States, it should verify product specifications, lot numbers, and UDI identifiers to confirm whether the product is affected by this recall. Even if the product is not listed, companies should proactively assess tubing air risk, especially under pressure infusion or fully open flushing conditions.

Second, for similar products that have obtained FDA 510(k) or PMA registration, companies should review performance validation data in the technical file to ensure that no air ingress risk exists under intended use conditions. If differences are identified, additional testing and a change submission may be needed, or labeling may need to be updated to include warnings. For example, instructions for use could add a caution to check for air bubbles in the tubing when using a pressure cuff.

Third, in terms of quality systems, companies should strengthen post-market surveillance (PMS) processes. FDA requires manufacturers to actively collect and analyze complaints and adverse events. In this alert, Baxter has sent letters to customers; companies should establish similar mechanisms to initiate risk assessment and corrective and preventive actions immediately when similar issues are identified. Distributors and users must be able to contact the company quickly to report problems.

Fourth, for devices already marketed in the United States that involve this risk, companies should immediately check inventory and distribution channels and conduct a user-level recall as required by FDA. Even if not selling directly, companies acting as OEMs or suppliers should trace and notify downstream customers. Companies are advised to maintain communication with FDA and submit MDR reports in a timely manner.

Finally, this event highlights the importance of the UDI system. Companies should ensure that product UDI codes are correctly encoded and accurately listed in the GUDID database so that products can be quickly located in similar recalls. Companies registered with China NMPA should also apply this logic to domestic adverse event monitoring systems and implement product traceability and feedback mechanisms.

Business Impact

From an international medical device registration perspective, information published in FDA CDRH News & Updates should not be read only as general news. Companies should first determine whether it relates to regulatory policy, guidance and standards, product approval, recall/safety, quality systems, or post-market regulatory information, because different types of information require different internal actions. If a company is progressing a registration project in the relevant market, the update should be added to the target-market regulatory tracking table to confirm whether it affects product classification, registration pathway, applicant responsibilities, local agent responsibilities, or certificate maintenance arrangements.

For Chinese medical device companies, the direct impact of the FDA Early Alert on Baxter intravascular administration sets issued on July 9, 2026 is typically reflected in documentation consistency and evidence-chain management. Companies need to review existing technical files, risk management reports, performance validation data, clinical evaluation or clinical evidence, labels and instructions for use, quality system certificates, and post-market surveillance documents to confirm whether these materials still support the latest regulatory expectations in the target market. If the information involves safety notices, recalls, product approvals, or regulatory meetings, companies should also assess whether similar products, similar technology routes, or similar risk points may receive increased attention from reviewers.

At the implementation level, AIMEILI recommends three actions: first, record the official source link, publication date, applicable product scope, and potentially affected areas in the regulatory tracking ledger; second, have regulatory, quality, R&D, and sales functions jointly determine whether labels, instructions for use, clinical evaluation, risk management, or test reports need to be updated; third, if the company has already marketed the product locally or submitted a registration application, assess whether the local agent, importer, distributor, and after-sales team need to take communication, change, supplementary explanation, or post-market surveillance measures.

The value of this type of news is not simply knowing what a regulator has published, but converting public information into executable compliance actions. For companies preparing for multi-country registration, particular attention should be paid to the boundaries of document reuse: the same CE, FDA, NMPA, ISO 13485, or MDSAP documentation may serve as core evidence in one country but may require localized explanations, language labeling, authorized representative documents, or post-market maintenance plans in another country. AIMEILI recommends that companies conduct a brief documentation gap review after each important regulatory update to avoid reactive corrections, changes, or certificate renewals later.

FAQ

Does an update to an FDA public page always mean a regulatory change?

No. It is necessary to distinguish among news, guidance, database pages, recall information, and formal regulatory documents. Important content should be assessed against the original FDA text and applicable regulations.

What should companies do after seeing an FDA update?

Companies should first determine whether it affects product classification, registration pathway, technical documentation, or post-market obligations, and then decide whether to update the project plan.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI International Medical Device Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.

Scope: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.

Continue Reading

Previous article: No update available

Next article: July 14, 2026 FDA Seeks Comments on Certain Non-Device Software Functions

Related articles: July 14, 2026 FDA Seeks Comments on Certain Non-Device Software Functions; WHO Publishes Safety Assessment of Contaminants in Food; May 23, 2026 FDA Issues Recall Notice for Abiomed 14Fr Low-Profile Introducer Kit; FDA Publishes FAQs on Market Access for Radiation-Emitting Electronic Products; ANMAT Introduces Simplified Licensing System for Low-Risk Medical Device Manufacturing and Importing Establishments; May 26, 2026 Austria BASG Warns About Non-Compliant Sexually Transmitted Disease Self-Tests Sold Online.

Return to News; View FAQ Center.

Need to assess a registration pathway? Please provide the product name, intended use, target countries, and available documentation basis. AIMEILI can assist in determining the registration pathway, documentation gaps, and compliance risks. Contact AIMEILI.